Navigation Links
FDA Investigating Weight-Loss Drug Over Reports of Liver Damage
Date:8/25/2009

32 cases reported since orlistat came on market in 1999

TUESDAY, Aug. 25 (HealthDay News) -- As U.S. health officials announced Monday that they are investigating the weight-loss drug orlistat for possible incidents of liver damage, experts noted the drug might not even work well enough to warrant such potential risks.

Orlistat is available in the United States, both as a prescription product (Xenical) and as an over-the-counter medication (Alli).

Depending on the findings from the investigation, this could dramatically change the risk-benefit ratio of taking the drug, experts noted.

The weight loss gleaned from the drug is quite modest, about 5 kilograms, said Dr. Timothy Pfanner, an assistant professor of internal medicine at the Texas A&M Health Science Center College of Medicine and a gastroenterologist with Scott & White, in Temple, Texas.

"It's not a really effective drug. The benefit is not so great to begin with," he said, and additional risks might simply make the drug that much less attractive.

The other problem is that many obese people already have underlying liver problems, added Dr. Eugene Schiff, director of the Center for Liver Diseases at the University of Miami Miller School of Medicine.

"If they [the Food and Drug Administration] feel there is a subgroup, albeit a small one but a real one, that gets a serious liver injury, [that] often will be compounded by the fact they have underlying liver disease," he said. "It's very important that this be resolved quickly."

The issue is complicated by the fact that some patients are taking the drug in its over-the-counter form, meaning they are likely not being tracked and monitored by doctors for side effects.

At this point, there is no reason for consumers to stop taking the drug if they're already on it -- as long as they're using it as recommended -- and no reason for physicians to stop prescribing it, U.S. Food and Drug Administration officials stressed Monday.

But the agency does recommend that patients tell their doctor if they are having symptoms such as weakness, fatigue, fever, jaundice or brown urine. Abdominal pain, nausea, vomiting, light-colored stools, itching and loss of appetite might also signal trouble.

Monday's move follows reports of 32 cases of serious liver injury, including six cases of liver failure, between 1999 and October of 2008.

More commonly, patients reported having jaundice, weakness and abdominal pain. For 27 patients, the symptoms were severe enough to require hospitalization.

Two of the cases occurred in the United States, the rest originated overseas.

In 10 years of being on the market, this isn't a great number, Pfanner noted.

The Drug Safety Oversight Board, part of FDA's Center for Drug Evaluation and Research, first looked into the issue in April. The agency stressed that there is no established association or evidence of a cause-and-effect relationship at this time.

The FDA first approved orlistat as a prescription medicine in 1999. In 2007, it became the first nonprescription drug approved to treat obesity in American adults.

The prescription version of the drug comes in 120-milligram capsules while the over-the-counter version is available in 60-milligram pills. Both versions are designed only to be used in conjunction with a reduced-calorie, low-fat diet by overweight adults aged 18 and older.

In 2006, the consumer advocacy group Public Citizen petitioned the FDA to remove Xenical from the U.S. market, not because of liver-related issues but because it might increase the risk of aberrant crypt foci, believed to be precursors to colon cancer.

The FDA's approval of the first over-the-counter drug for weight loss came as the United States and other western nations are struggling with an unprecedented obesity epidemic.

According to the U.S. National Center for Health Statistics, 30 percent of American adults aged 20 and older -- more than 60 million people -- are obese. Another 36 percent are considered overweight.

Orlistat is also approved in some 100 countries, with an over-the-counter form available in the European Union.

More information

The U.S. National Library of Medicine has more on orlistat.



SOURCES: Eugene Schiff, M.D., professor, medicine, and director, Center for Liver Diseases, University of Miami Miller School of Medicine; Timothy Pfanner, M.D., assistant professor, internal medicine, Texas A&M Health Science Center College of Medicine, and gastroenterologist, Scott & White; Aug. 24, 2009, news release, U.S. Food and Drug Administration


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations
2. FDA Investigating Safety of Asthma Drug Xolair
3. DEA Will Play Hardball in Investigating Michael Jacksons Doctors
4. Forensic Expert Investigating Chinese Drywall Issue
5. FDA Investigating Salmonella-Tainted Pistachios
6. Investigating a community where smoking rates are double the national average
7. Investigating causes of asthma attacks: New sensor system monitors environmental exposure
8. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
9. Consumer Specialty Products Association Responds to European Study Investigating Spray Products and Asthma
10. UT Southwestern investigating hypothermic technique in treating pediatric head injuries
11. Study Finds Weight-Loss Surgery Safer Than Thought
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Investigating Weight-Loss Drug Over Reports of Liver Damage
(Date:6/28/2017)... , ... June 28, 2017 , ... ... is pleased to announce that a two year study conducted by the University ... Creek zeolite was successful in remediating potash brine-impacted groundwater. As a part of ...
(Date:6/27/2017)... ... June 27, 2017 , ... Excel Medical, the ... to the position of Executive Vice President, Sales and Marketing. Finnegan is a ... and medical device sales leadership. He has received industry recognition for innovations and ...
(Date:6/27/2017)... ... June 27, 2017 , ... The Congressional Budget Office (CBO) projects that ... the 2010 Patient Protection and Affordable Care Act (ACA), would result in 22 million ... under current law. , More than 20 million Americans have gained health insurance under ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... management assistance and personal financial planning services to residents of southern New Hampshire, ... charity event that promises to fight hunger and homelessness in the region. , ...
(Date:6/27/2017)... ... June 27, 2017 , ... Hammer Strength, the world’s leading ... named Javair Gillett of the Houston Rockets the NBSCA Strength & Conditioning Coach of ... decided by NBSCA members who vote to select the coach who embodies the highest ...
Breaking Medicine News(10 mins):
(Date:6/27/2017)... , Jun 27, 2017   NuEyes (NuEyes ... of funding to fuel its growth in helping the legally ... (Osterhout Design Group), the leading developer of augmented, virtual ... technology sits. The undisclosed funding amount was provided ... firm, Arab Angel, with offices in Abu Dhabi ...
(Date:6/16/2017)... BOSTON , June 16, 2017  Exactly 50 years ... kicked off what later became known as the San Francisco ... www.northernlight.com ) is unveiling two radical innovations in strategic market ... summer.  This announcement marks the beginning of Northern Light,s "Summer ... ...
(Date:6/12/2017)... Inc., a biotechnology company focused on the development of novel ... and Head of Virology Kristin Bedard has been invited to ... Beyond meeting sponsored by Life Science Washington.  This Symposium ... PDT at the Agora Conference Center in Seattle, ... joined by other leaders in infectious disease research and the ...
Breaking Medicine Technology: